Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis

Pancreatology ◽  
2016 ◽  
Vol 16 (6) ◽  
pp. 1124-1128 ◽  
Author(s):  
Yanming Zhou ◽  
Ailing Song ◽  
Lupeng Wu ◽  
Xiaoying Si ◽  
Yumin Li
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Pooled Analysis ◽  
Ductal Adenocarcinoma ◽  
Remnant Pancreas

Development of metachronous or recurrent lesion in the remnant pancreas after partial pancreatectomy for pancreatic ductal adenocarcinoma

Pancreatology ◽  
2016 ◽  
Vol 16 (4) ◽  
pp. S45
Author(s):  
Yoshitaka Gotoh ◽  
Takao Ohtsuka ◽  
Yohei Nakama ◽  
Kenjiro Date ◽  
Takaaki Fujimoto ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Partial Pancreatectomy ◽  
Recurrent Lesion ◽  
Remnant Pancreas

scholarly journals Development of Pancreatic Ductal Adenocarcinoma Associated with Intraductal Papillary Mucinous Neoplasia

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Kazuo Inui ◽  
Junji Yoshino ◽  
Hironao Miyoshi ◽  
Takashi Kobayashi ◽  
Satoshi Yamamoto
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Magnetic Resonance Cholangiopancreatography ◽  
Ductal Adenocarcinoma ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Cancer Occurrence ◽  
Remnant Pancreas ◽  
Mucinous Neoplasms ◽  
Group 2 ◽  
Enhanced Computed Tomography ◽  
Periodic Evaluation

We retrospectively investigated the incidence of pancreatic ductal adenocarcinoma among patients with intraductal papillary mucinous neoplasms of the pancreas. Based on imaging in 195 such patients, we chose surgery as initial treatment for 54, and periodic evaluation over 6 to 192 months (mean, 52) for 141. In 6 of the 141 patients observed for intraductal papillary mucinous neoplasm (4.2%), pancreatic ductal adenocarcinoma developed. Further, careful monitoring for cancer occurrence in the remnant pancreas proved essential in the surgical resection group; 2 of 26 patients (7.7%) subsequently developed pancreatic ductal adenocarcinoma in the remnant pancreas, at 41 months and 137 months after surgery. Serial observation of patients with intraductal papillary mucinous neoplasms by contrast-enhanced computed tomography or magnetic resonance cholangiopancreatography therefore is critical, whether or not surgical treatment initially was performed.

scholarly journals Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Pooled Analysis

2020 ◽  
Vol 9 (12) ◽  
pp. 3945
Author(s):  
Munseok Choi ◽  
Na Won Kim ◽  
Ho Kyoung Hwang ◽  
Woo Jung Lee ◽  
Chang Moo Kang
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Local Recurrence ◽  
Pooled Analysis ◽  
Ductal Adenocarcinoma ◽  
Time Interval ◽  
Remnant Pancreas ◽  
Recurrent Pancreatic Cancer ◽  
Isolated Local Recurrence

The mainstream treatment for recurrent pancreatic cancer is potent chemotherapy or chemoradiotherapy. However, recent clinical investigations have suggested a potential oncologic role of local resection of recurrent pancreatic cancer. This systemic review with a pooled analysis aimed to assess the potential role of local repeated pancreatectomy with respect to the survival outcomes for patients with recurrent pancreatic ductal adenocarcinoma (PDAC) in the remnant pancreas. The PubMed database was searched, and 15 articles reporting on repeated pancreatectomy for local recurrence of PDAC in the remnant pancreas were identified. The pooled individual data were examined for the clinical outcomes of repeated pancreatectomy for recurrent PDAC. The survival analysis was performed using the Kaplan–Meier method. In the pooled analysis, the mean time interval from initial pancreatectomy to repeated pancreatectomy was 41.3 months (standard deviation (SD), 29.09 months). Completion total pancreatectomy was most commonly performed as repeated pancreatectomy (46 patients, 92.0%), and partial pancreatic resection was performed for only 4 (10.3%) patients. Twenty (40.9%) patients received postoperative chemotherapy following repeated pancreatectomy. The median overall survival was 60 months (95% confidential interval (CI): 45.99–74.01) after repeated pancreatectomy for isolated local recurrence in the remnant pancreas. Overall survival was markedly longer considering the timing of the initial pancreatectomy for pancreatic cancer (median, 107 months (95% CI: 80.37–133.62). The time interval between the initial and subsequent repeated pancreatectomy for pancreatic cancer was not associated with long-term oncologic outcomes (p = 0.254). Repeated pancreatectomy cannot completely replace adjuvant chemotherapy but should be considered for patients with isolated local recurrent PDAC in the remnant pancreas.

Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma

2000 ◽  
Vol 15 (11) ◽  
pp. 1333-1338 ◽  
Author(s):  
Koji Uno ◽  
Takeshi Azuma ◽  
Masatsugu Nakajima ◽  
Kenjiro Yasuda ◽  
Takanobu Hayakumo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Significance ◽  
Pancreatic Juice ◽  
Ductal Adenocarcinoma ◽  
Cathepsin E
Sign in / Sign up

Export Citation Format

Share Document